# Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR

> **NCT00216398** · PHASE4 · COMPLETED · sponsor: **Ipsen** · enrollment: 8 (actual)

## Conditions studied

- Acromegaly

## Interventions

- **DRUG:** Lanreotide (Autogel formulation)

## Key facts

- **NCT ID:** NCT00216398
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2006-06-22
- **Final completion:** 2006-06-22
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2019-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00216398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00216398, "Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00216398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*